Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$26.14
$0.55(10.50%)
At close: 4:00 PM EST
$26.14
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.08M
Market Cap
$2.02B
Enterprise Value$2.03B
Total Cash (Recent Filing)$328.96M
Total Debt (Recent Filing)$4.48M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Mar 02, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding78,659,920
10 Day Avg. Volume844,597
30 Day Avg. Volume1,081,431
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.82K
Enterprise Value/Ebitda-12.56
Forecast
1Y Price Target
$42.67Price Target Upside63.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Adjuvant Market Expansion OpportunityPositive data for oral SERDs supports the strategic case for expanding palazestrant into the adjuvant setting, which could materially enlarge Olema's addressable market if a funding or partner arrangement is secured.
Clinical Readthrough From Competitor TrialPositive Phase 3 results from Roche's lidERA trial provide a readthrough that increases confidence in Olema's OPERA-02 oral SERD plus CDK4/6 inhibitor program and its chance of achieving favorable efficacy outcomes.
Therapeutic Differentiation With RibociclibPalazestrant's combination development with ribociclib may offer a therapeutic advantage compared with palbociclib-based regimens, supporting potential clinical differentiation in frontline ER+/HER2- breast cancer.
Bears Say
High-risk Rating And VolatilityA Buy/High Risk analyst rating signals elevated potential for pronounced share price volatility, increasing the likelihood of sharp moves for investors in OLMA.
Report Objectivity And Conflict RiskPotential business relationships of the reporting firm could create conflicts that undermine confidence in analyst coverage and affect how the market interprets commentary on OLMA.
Sentiment-driven Downside RiskNegative outcomes from competitor trials could trigger meaningful sentiment-driven selling in OLMA shares, causing sharp price pressure irrespective of Olema's own trial progress.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $2.02B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 25 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 11, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.015.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.52.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 78,659,920 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -5.862%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (63.24% Upside)
$42.67 (63.24% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
338.59%
12-Months-Change
Fundamentals
Return on Equity
-59.22%
Trailing 12-Months
Asset Growth
53.13%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$42.67
▲(63.24% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---